179 related articles for article (PubMed ID: 1520585)
1. A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer.
Haisma HJ; Boven E; van Muijen M; de Jong J; van der Vijgh WJ; Pinedo HM
Br J Cancer; 1992 Sep; 66(3):474-8. PubMed ID: 1520585
[TBL] [Abstract][Full Text] [Related]
2. Comparison of two anthracycline-based prodrugs for activation by a monoclonal antibody-beta-glucuronidase conjugate in the specific treatment of cancer.
Haisma HJ; van Muijen M; Pinedo HM; Boven E
Cell Biophys; 1994; 24-25():185-92. PubMed ID: 7736523
[TBL] [Abstract][Full Text] [Related]
3. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
[TBL] [Abstract][Full Text] [Related]
4. A new application for liposomes in cancer therapy. Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of prodrugs.
Vingerhoeds MH; Haisma HJ; van Muijen M; van de Rijt RB; Crommelin DJ; Storm G
FEBS Lett; 1993 Dec; 336(3):485-90. PubMed ID: 8282116
[TBL] [Abstract][Full Text] [Related]
5. Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): optimization of prodrug activating capacity.
Vingerhoeds MH; Haisma HJ; Belliot SO; Smit RH; Crommelin DJ; Storm G
Pharm Res; 1996 Apr; 13(4):604-10. PubMed ID: 8710754
[TBL] [Abstract][Full Text] [Related]
6. Improved characteristics of a human beta-glucuronidase-antibody conjugate after deglycosylation for use in antibody-directed enzyme prodrug therapy.
Houba PH; Boven E; Haisma HJ
Bioconjug Chem; 1996; 7(5):606-11. PubMed ID: 8889024
[TBL] [Abstract][Full Text] [Related]
7. Characterization of novel anthracycline prodrugs activated by human beta-glucuronidase for use in antibody-directed enzyme prodrug therapy.
Houba PH; Leenders RG; Boven E; Scheeren JW; Pinedo HM; Haisma HJ
Biochem Pharmacol; 1996 Aug; 52(3):455-63. PubMed ID: 8687500
[TBL] [Abstract][Full Text] [Related]
8. Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug.
Cheng TL; Wei SL; Chen BM; Chern JW; Wu MF; Liu PW; Roffler SR
Br J Cancer; 1999 Mar; 79(9-10):1378-85. PubMed ID: 10188879
[TBL] [Abstract][Full Text] [Related]
9. Cure of malignant ascites and generation of protective immunity by monoclonal antibody-targeted activation of a glucuronide prodrug in rats.
Chen BM; Chan LY; Wang SM; Wu MF; Chern JW; Roffler SR
Int J Cancer; 1997 Nov; 73(3):392-402. PubMed ID: 9359487
[TBL] [Abstract][Full Text] [Related]
10. Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: comparison with the corresponding antibody-enzyme conjugate.
Fonseca MJ; Jagtenberg JC; Haisma HJ; Storm G
Pharm Res; 2003 Mar; 20(3):423-8. PubMed ID: 12669963
[TBL] [Abstract][Full Text] [Related]
11. Analysis of a conjugate between anti-carcinoembryonic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphate.
Haisma HJ; Boven E; van Muijen M; De Vries R; Pinedo HM
Cancer Immunol Immunother; 1992; 34(5):343-8. PubMed ID: 1540981
[TBL] [Abstract][Full Text] [Related]
12. Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy.
Wang SM; Chern JW; Yeh MY; Ng JC; Tung E; Roffler SR
Cancer Res; 1992 Aug; 52(16):4484-91. PubMed ID: 1643640
[TBL] [Abstract][Full Text] [Related]
13. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
[TBL] [Abstract][Full Text] [Related]
14. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue.
Chen KC; Schmuck K; Tietze LF; Roffler SR
Mol Pharm; 2013 May; 10(5):1773-82. PubMed ID: 23448264
[TBL] [Abstract][Full Text] [Related]
15. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
Biela BH; Khawli LA; Hu P; Epstein AL
Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
[TBL] [Abstract][Full Text] [Related]
16. Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy.
Fonseca MJ; Storm G; Hennink WE; Gerritsen WR; Haisma HJ
J Gene Med; 1999; 1(6):407-14. PubMed ID: 10753066
[TBL] [Abstract][Full Text] [Related]
17. A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas.
Zhang L; Fang Y; Kopeček J; Yang J
Eur J Pharm Sci; 2017 May; 103():36-46. PubMed ID: 28249824
[TBL] [Abstract][Full Text] [Related]
18. Poly(ethylene glycol) modification of beta-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs.
Cheng TL; Chen BM; Chan LY; Wu PY; Chern JW; Roffler SR
Cancer Immunol Immunother; 1997 Aug; 44(6):305-15. PubMed ID: 9298932
[TBL] [Abstract][Full Text] [Related]
19. Pronounced antitumor efficacy by extracellular activation of a doxorubicin-glucuronide prodrug after adenoviral vector-mediated expression of a human antibody-enzyme fusion protein.
de Graaf M; Pinedo HM; Oosterhoff D; van der Meulen-Muileman IH; Gerritsen WR; Haisma HJ; Boven E
Hum Gene Ther; 2004 Mar; 15(3):229-38. PubMed ID: 15018732
[TBL] [Abstract][Full Text] [Related]
20. Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy.
Leu YL; Chen CS; Wu YJ; Chern JW
J Med Chem; 2008 Mar; 51(6):1740-6. PubMed ID: 18318465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]